FierceBiotechOriginal article
{"a":[{"_":"Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis","$":{"href":"/biotech/ipsen-pens-17b-deal-acquire-kartos-potential-jakafi-add-therapy-myelofibrosis","hreflang":"en"}}]}
JakafiKartos Phase 3 drugPositive
AI Analysis
Summary
Ipsen is acquiring U.S.-based Kartos Therapeutics for $1.7B ($450M upfront) to gain a Phase 3 blood cancer drug designed as a potential add-on therapy to Jakafi for myelofibrosis treatment.
Clinical Trial Data
Phase
Phase 3
Importance:7/10
Sentiment:
0.60
M&AacquisitiononcologymyelofibrosisPhase 3
Related Companies
Read the original article
Published by FierceBiotech on June 29, 2026 4:44 AM